Fig. 1 · Structure

Documents & Downloads

Danusertib (PHA-739358)

Cat. No. A10715 CAS 827318-97-8

Aurora inhibitor

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2

In Stock

Publications for Danusertib

1 publication citing this product

  1. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Danusertib binds Aurora A through a multistep process involving conformational selection and induced fit. Biophysical measurements at 25°C found nanomolar affinity and slow release from the drug-bound state; these binding measurements are distinct from kinase-inhibition IC50 values. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AuroraA IC50 13nM
Abl IC50 25nM
RET IC50 31nM
TrkA IC50 31nM
FGFR1 IC50 47nM
AuroraC IC50 61nM
AuroraB IC50 79nM

7 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 IC50 0.031 μM Antiproliferative activity against human HCT116 cells assessed as BrdU incorporation after 72 hrs [PMID: 19320489]
HCT-116 EC50 80 nM Cell cycle arrest in HCT116 cells by accumulation at G2/M phase [PMID: 17125279]
HeLa IC50 > 25 μM Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay [PMID: 30647879]
MOLT-4 EC50 0.15 μM Cytotoxicity against human MOLT4 cells assessed as inhibition of cell growth after 4 days by Cell Titer Blue end-point assay [PMID: 22889561]

Danusertib (PHA-739358) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Danusertib (PHA-739358) from 2 published references.

Danusertib (PHA-739358) In Vitro Studies

In human ALL cells, 1 μM PHA-739358 for 24 h reduced Bcr/Abl-associated phosphorylation signals in BLQ1 and UCSF02 and reduced histone H3 Ser10 phosphorylation in BLQ1 and Ph-negative US6. These cellular readouts support pathway modulation without establishing exclusive target selectivity. [2]

Danusertib binding and dissociation kinetics at Aurora A

Biochemical assay · Recombinant dephosphorylated human Aurora A kinase domain (residues 122–403); biotinylated T288V variant for surface-immobilized Creoptix WAVE measurements. [1]

Orthogonal binding measurements and global kinetic fitting support conformational selection followed by an induced-fit step. The fitted reverse conformational step differs from the observed slow-off rate; neither is a cellular IC50. Affinity estimates are assay-specific.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Equilibrium binding affinity to surface-immobilized Aurora A T288VKD 1.1 ± 0.4 nM[1]
Equilibrium binding affinity to solution-phase dephosphorylated Aurora AKD 0.4 ± 0.1 nM[1]
Observed slow dissociation after dilution of preformed Aurora A–danusertib complexObserved off-rate (3.2 ± 0.3) × 10^-4 s^-1[1]

Literature-Reported Treatment Conditions

Treatment concentration
WAVE binding Methods: 0.13–66.67 nM danusertib; Figure 5G caption lists plotted series 0.1–64.8 nM. Fluorescence titration supplement: 0–11.25 nM. Slow-off assay: 30 nM Aurora A plus 30 nM danusertib before 30-fold dilution.
Exposure duration
Slow-off complex preincubated 1 h; fluorescence recorded every 160 s over 6 h. Equilibrium titration used 5 min equilibration after each addition.
Method
Binding/kinetic measurements at 25°C; stopped-flow traces averaged from replicate measurements and globally fitted with KinTek Explorer. WAVE reference channel and fluorimeter photobleaching control described in Methods.
Vehicle
DMSO drug stocks; stopped-flow buffer contained 5% DMSO. WAVE buffer formulation reported separately; final drug-derived DMSO fraction for danusertib WAVE binding not specified.
Reported limits
No cellular potency inferred. Figure-specific concentration series and Methods ranges are retained separately. The same-study solution and surface affinity estimates are not pooled; cause of their difference is not established.
Methods and source locations

Compound reported in the paper: Danusertib; Compound label in the paper: Danusertib (PHA739358)

Compound-level research evidence; the studies do not validate Adooq A10715, its lot, purity, salt form or stereochemistry. No salt or dose conversion applied.

Results: Kinetics of Danusertib binding to Aurora A; Figure 5B–I, Figure 6; Figure 5 supplements 1–2; Methods: stopped-flow, Creoptix WAVE, spectrofluorometer and macroscopic dissociation constant experiments

Equilibrium binding affinity to surface-immobilized Aurora A T288V: Creoptix WAVE waveguide interferometry at 25°C; equilibrium surface signal fitted against concentration. Figure 5 caption describes uncertainty as SD of fitted parameter. — Figure 5G–H and caption; Creoptix WAVE Methods

Equilibrium binding affinity to solution-phase dephosphorylated Aurora A: Tryptophan-fluorescence titration at 25°C; change at 368 nm fitted to Equation 6. Uncertainty is SD in fitted parameter per specific caption. — Figure 5—figure supplement 1D and caption; Macroscopic dissociation constant Methods

Observed slow dissociation after dilution of preformed Aurora A–danusertib complex: Fluorimeter at 25°C, 30-fold dilution after 1 h preincubation; single-exponential fit, with drug-free photobleaching control. Specific Figure 5 caption defines uncertainty as fitted-parameter SD. — Figure 5E and caption; Spectrofluorometer Methods

Cellular Bcr/Abl-associated and Aurora B substrate modulation

Cell-based study · Human ALL samples BLQ1 (Bcr/Abl T315I), UCSF02 (wild-type Bcr/Abl), and US6 (Ph-negative); stromal support as described in shared methods. [2]

PHA-739358 reduced phosphotyrosine, phospho-Stat5 and phospho-Crkl signals in BLQ1 and UCSF02. It also reduced the phospho-histone H3 (Ser10)-positive population in BLQ1 and US6. Dasatinib alone inhibited the wild-type sample but lacked the corresponding effect in BLQ1. These are cellular pathway/substrate readouts, not direct isoform-selective biochemical inhibition constants.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphotyrosine, phospho-Stat5 and phospho-Crkl signalsQualitative immunoblot response Decreased with 1 μM PHA-739358 after 24 h in BLQ1 and UCSF02[2]
Histone H3 Ser10 phosphorylation-positive cell populationQualitative flow-cytometry response Reduced after 1 μM PHA-739358 for 24 h in BLQ1 and US6[2]

Literature-Reported Treatment Conditions

Treatment concentration
PHA-739358: 1 μM for selected comparisons; Figure 3A also tests 0.5 and 5 μM. Dasatinib comparator: 100 nM.
Exposure duration
24 h for selected readouts; Figure 3B additionally shows 48 h.
Method
In vitro exposure followed by immunoblotting or phospho-histone H3 flow cytometry; not a viability IC50 assay.
Vehicle
DMSO stock; final cellular DMSO concentration not specified in the read Methods. Untreated controls are shown.
Co-treatment
Selected evidence is PHA-739358 monotherapy; dasatinib-alone and combined-treatment lanes are contextual comparators.
Reported limits
Exact p-H3 fractions excluded owing to text/figure disagreement; no quantitative blot densitometry or biological replicate count specified for Figure 3. Final vehicle concentration is not specified.
Methods and source locations

Compound reported in the paper: Danusertib (PHA-739358); Compound label in the paper: PHA-739358

Compound-level research evidence; the studies do not validate Adooq A10715, its lot, purity, salt form or stereochemistry. No salt or dose conversion applied.

Results: PHA-739358 targets both Bcr/Abl and Aurora kinase activities; Figure 3A–B and caption; Methods: Drugs, reagents and cells, Western blotting, Assessment of phosphorylation status of histone H3 by flow cytometry

Phosphotyrosine, phospho-Stat5 and phospho-Crkl signals: Western blot; Bcr, Src and GAPDH loading/reprobing controls. Figure 3A includes PHA-739358 alone, dasatinib alone (100 nM), and combination lanes; selected result uses monotherapy lanes. — Figure 3A, caption and accompanying Results

Histone H3 Ser10 phosphorylation-positive cell population: Phospho-histone H3 antibody flow cytometry with untreated controls; Figure 3B also shows 48 h. No exact percentage selected because text and plotted labels disagree. — Figure 3B and caption; Histone H3 flow-cytometry Methods

Danusertib (PHA-739358) In Vivo Studies

In a Pt2 Bcr/Abl T315I ALL mouse model, intravenous PHA-739358 at 30 mg/kg once daily on a 7-days-on/7-days-off schedule for three cycles extended median survival to 77 days versus 59 days with vehicle (n = 8 per group; p = 0.0002). Leukemia persisted and rebounded after treatment ended. [2]

Survival and leukemia progression in a human ALL mouse model

Animal study · Female NSG mice bearing human Pt2 Philadelphia-positive ALL with Bcr/Abl T315I; n = 8 per treatment group. [2]

Intermittent PHA-739358 monotherapy prolonged median survival and suppressed circulating leukemia during treatment compared with vehicle. Leukemia persisted and increased after treatment ended; the authors explicitly describe disease reduction without cure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Overall survival after leukemia-cell transplantationMedian survival 77 days (PHA-739358) versus 59 days (vehicle); n = 8 per group; p = 0.0002[2]
Circulating CD10+CD19+ leukemia-cell burdenQualitative longitudinal response Suppressed during treatment; increased again after treatment termination[2]

Conditions shared by the study groups

Route
Intravenous
Frequency
Once daily during each treatment week.
Treatment course
7 days on / 7 days off, for 3 cycles.
Vehicle
Vehicle solution; composition not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PHA-739358 monotherapy
30 mg/kg
Vehicle-treated mice (n = 8).Median survival 77 versus 59 days; p = 0.0002. Circulating leukemia was suppressed but not eliminated and rebounded after treatment stopped.[2]
PHA-739358 monotherapy
Model: Pt2 Bcr/Abl T315I human ALL in female NSG mice; n = 8 drug-treated and n = 8 vehicle controls.
Reported limits: The separate 45 mg/kg acute pharmacodynamic experiment (Figure 5) is not this survival regimen. Timeline onset differs by one day between Methods and graph.
Methods and source locations

Compound reported in the paper: Danusertib (PHA-739358); Compound label in the paper: PHA-739358

Compound-level research evidence; the studies do not validate Adooq A10715, its lot, purity, salt form or stereochemistry. No salt or dose conversion applied.

Results: In vivo efficacy of PHA-739358 on Bcr/Abl cells with T315I mutation; Figure 6A–E and caption; Methods: Evaluation of PHA-739358 in vivo and Statistical analysis

Overall survival after leukemia-cell transplantation: Survival follow-up; medians reported in Results, significance and group sizes in Figure 6C caption. The read statistical Methods does not identify a survival-specific test. — Figure 6C and caption; In vivo efficacy Results

Circulating CD10+CD19+ leukemia-cell burden: Peripheral-blood flow cytometry. Text and Figure 6A/B contain differing approximate percentages; no exact burden values selected. — Figure 6A–B; In vivo efficacy Results and Discussion

PHA-739358 monotherapy · Results: In vivo efficacy of PHA-739358 on Bcr/Abl cells with T315I mutation; Figure 6A–E and caption; Methods: Evaluation of PHA-739358 in vivo and Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 827318-97-8
Applications Aurora inhibitor
Formula C26H30N6O3
Molecular Weight 474.6
Synonyms PHA-739358
SMILES
CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)[C@@H](C5=CC=CC=C5)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (195.97 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Danusertib (PHA-739358) Research References

  1. [1] Warintra Pitsawong, Vanessa Buosi, Renee Otten, et al. Dynamics of human protein kinase Aurora A linked to drug selectivity. eLife (2018). PMID: 29901437 DOI: 10.7554/elife.36656 Source material
  2. [2] Fei Fei, Min Lim, Sabine Schmidhuber, et al. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Molecular cancer (2012). PMID: 22721004 DOI: 10.1186/1476-4598-11-42 Source material

Publications

1 publication citing this product

  1. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138

Added to your cart

View Cart Checkout
Loading...